ATE288431T1 - Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum - Google Patents

Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum

Info

Publication number
ATE288431T1
ATE288431T1 AT01938484T AT01938484T ATE288431T1 AT E288431 T1 ATE288431 T1 AT E288431T1 AT 01938484 T AT01938484 T AT 01938484T AT 01938484 T AT01938484 T AT 01938484T AT E288431 T1 ATE288431 T1 AT E288431T1
Authority
AT
Austria
Prior art keywords
bizyclic
derivatives
substituted
treatment
cell growth
Prior art date
Application number
AT01938484T
Other languages
German (de)
English (en)
Inventor
John Charles Kath
Samit Kumar Bhattacharya
Joel Morris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE288431T1 publication Critical patent/ATE288431T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01938484T 2000-06-22 2001-06-14 Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum ATE288431T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22
PCT/IB2001/001046 WO2001098277A2 (en) 2000-06-22 2001-06-14 Substituted bicyclic derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
ATE288431T1 true ATE288431T1 (de) 2005-02-15

Family

ID=22793862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01938484T ATE288431T1 (de) 2000-06-22 2001-06-14 Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum

Country Status (42)

Country Link
US (2) US6890924B2 (en, 2012)
EP (1) EP1292591B1 (en, 2012)
JP (1) JP4044839B2 (en, 2012)
KR (1) KR100545537B1 (en, 2012)
CN (3) CN1437594A (en, 2012)
AP (1) AP2001002192A0 (en, 2012)
AR (1) AR032353A1 (en, 2012)
AT (1) ATE288431T1 (en, 2012)
AU (1) AU2001264159A1 (en, 2012)
BG (1) BG107269A (en, 2012)
BR (1) BR0111548A (en, 2012)
CA (1) CA2413424C (en, 2012)
CZ (1) CZ20023951A3 (en, 2012)
DE (1) DE60108754T2 (en, 2012)
DK (1) DK1292591T3 (en, 2012)
DZ (1) DZ3407A1 (en, 2012)
EA (1) EA005525B1 (en, 2012)
EC (1) ECSP024393A (en, 2012)
EE (1) EE200200710A (en, 2012)
ES (1) ES2236240T3 (en, 2012)
GE (1) GEP20063831B (en, 2012)
HR (1) HRP20021005A2 (en, 2012)
HU (1) HUP0301120A2 (en, 2012)
IL (1) IL152985A0 (en, 2012)
IS (1) IS6616A (en, 2012)
MA (1) MA26914A1 (en, 2012)
MX (1) MXPA02012870A (en, 2012)
MY (1) MY127181A (en, 2012)
NO (1) NO20026166L (en, 2012)
NZ (1) NZ522568A (en, 2012)
OA (1) OA12291A (en, 2012)
PA (1) PA8520301A1 (en, 2012)
PE (1) PE20020257A1 (en, 2012)
PL (1) PL359557A1 (en, 2012)
PT (1) PT1292591E (en, 2012)
SK (1) SK17102002A3 (en, 2012)
SV (1) SV2002000504A (en, 2012)
TN (1) TNSN01091A1 (en, 2012)
UA (1) UA73990C2 (en, 2012)
WO (1) WO2001098277A2 (en, 2012)
YU (1) YU95102A (en, 2012)
ZA (1) ZA200210231B (en, 2012)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR20010089284A (ko) * 1998-10-01 2001-09-29 다비드 에 질레스 화합물
UA73990C2 (en) * 2000-06-22 2005-10-17 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cells growth
TWI309647B (en, 2012) * 2001-02-21 2009-05-11 Mitsubishi Tanabe Pharma Corp
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
JP4220388B2 (ja) * 2001-11-30 2009-02-04 ファイザー・プロダクツ・インク 異常な細胞増殖を処置するための置換された二環式誘導体の製造方法
MXPA04005678A (es) * 2001-12-12 2004-12-06 Pfizer Prod Inc Formas de sal de e-2 -metoxi -n- (3- (4- (3-metil -piridin-3- iloxil ) fenilamino) quinazolin -6-il) alil) alil) acetamida, su preparacion y su uso contra el cancer.
BR0214499A (pt) * 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
NZ540092A (en) 2002-11-20 2007-06-29 Array Biopharma Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP2006513179A (ja) * 2002-12-18 2006-04-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のための４−アニリノキナゾリン誘導体
JP2006512355A (ja) * 2002-12-19 2006-04-13 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−｛４−［３−メチル−４−（６−メチルピリジン−３−イルオキシ）−フェニルアミノ］−キナゾリン−６−イル｝−アリル）−アセトアミドの複合体、それらの製造方法および使用
EP1615910A1 (en) * 2003-04-09 2006-01-18 Pfizer Products Inc. Processes for the preparation of n-((((pyridinyloxy)-phenylamino)quinazolinyl)-allyl)acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
MXPA05012839A (es) * 2003-05-27 2006-05-17 Pfizer Prod Inc Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa.
CN1984660B (zh) * 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005007184A2 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN102432552B (zh) * 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
KR20080014144A (ko) * 2003-08-18 2008-02-13 화이자 프로덕츠 인크. ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
HRP20080329T3 (en) 2003-09-16 2008-08-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
PT2210607E (pt) 2003-09-26 2012-01-31 Exelixis Inc N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolina-4-ilpropil)oxi]quinolina-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida para o tratamento do cancro
WO2005044302A1 (en) * 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005075439A1 (en) 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
BRPI0513200A (pt) 2004-07-16 2008-04-29 Pfizer Prod Inc uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
US20080200433A1 (en) * 2004-09-01 2008-08-21 Tsuyoshi Suzuki Molecular Chaperone Function Regulator
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
EA012970B1 (ru) 2005-04-26 2010-02-26 Пфайзер Инк. Антитела против р-кадгерина
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
SI2960253T1 (sl) 2005-09-07 2018-10-30 Amgen Fremont Inc. Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1
SG152230A1 (en) 2005-11-15 2009-05-29 Array Biopharma Inc Erbb inhibitors
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
JP4383525B2 (ja) 2006-05-09 2009-12-16 ファイザー・プロダクツ・インク シクロアルキルアミノ酸誘導体およびその医薬組成物
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
WO2008033749A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
RU2009126576A (ru) 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
WO2008127710A2 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
DK2245026T3 (da) 2008-02-07 2012-10-15 Boehringer Ingelheim Int Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
PE20091580A1 (es) 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
HRP20130458T4 (hr) 2009-01-16 2022-08-19 Exelixis Inc. MALATNA SOL OD N-(4-{[6,7-BIS(METILOKSI)KINOLIN-4-IL]OKSI} FENIL-N'-(4-FLUOROFENIL)CIKLOPROPAN-1,1-DIKARBOKSAMIDA I NJEZINI KRISTALNI OBLICI ZA LIJEČENJE RAKA\n
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
WO2013042006A1 (en) 2011-09-22 2013-03-28 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
CN102872018B (zh) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
ES2759434T3 (es) 2014-04-30 2020-05-11 Pfizer Derivados de diheterociclo unidos a cicloalquilo
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
WO2017148391A1 (zh) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3806887A4 (en) 2018-06-13 2022-04-06 California Institute of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
WO2020057511A1 (en) 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents
EP4501925A4 (en) * 2022-03-28 2025-08-27 Jiangsu Hengrui Pharmaceuticals Co Ltd NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
WO2025067396A1 (zh) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (en, 2012) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
KR100860295B1 (ko) 1998-10-08 2008-09-25 아스트라제네카 아베 퀴나졸린 유도체
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
UA73990C2 (en) * 2000-06-22 2005-10-17 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cells growth

Also Published As

Publication number Publication date
GEP20063831B (en) 2006-05-25
CN1576275A (zh) 2005-02-09
JP4044839B2 (ja) 2008-02-06
US6890924B2 (en) 2005-05-10
US20050159435A1 (en) 2005-07-21
CA2413424A1 (en) 2001-12-27
KR20030016303A (ko) 2003-02-26
TNSN01091A1 (fr) 2005-11-10
ES2236240T3 (es) 2005-07-16
US7332493B2 (en) 2008-02-19
MXPA02012870A (es) 2003-05-14
IL152985A0 (en) 2003-06-24
HK1069576A1 (en) 2005-05-27
PT1292591E (pt) 2005-06-30
EP1292591A2 (en) 2003-03-19
DZ3407A1 (en, 2012) 2001-12-27
PL359557A1 (en) 2004-08-23
EA005525B1 (ru) 2005-04-28
BG107269A (bg) 2003-06-30
BR0111548A (pt) 2003-05-06
UA73990C2 (en) 2005-10-17
IS6616A (is) 2002-11-14
NO20026166D0 (no) 2002-12-20
OA12291A (en) 2004-03-18
CN1437594A (zh) 2003-08-20
SK17102002A3 (sk) 2004-04-06
PA8520301A1 (es) 2003-06-30
AU2001264159A1 (en) 2002-01-02
HRP20021005A2 (en) 2004-02-29
YU95102A (sh) 2005-11-28
KR100545537B1 (ko) 2006-01-25
MY127181A (en) 2006-11-30
CZ20023951A3 (cs) 2004-01-14
US20020169165A1 (en) 2002-11-14
CA2413424C (en) 2007-10-02
DK1292591T3 (da) 2005-05-30
NZ522568A (en) 2004-12-24
CN101348467A (zh) 2009-01-21
CN1330640C (zh) 2007-08-08
EA200201277A1 (ru) 2003-06-26
WO2001098277A2 (en) 2001-12-27
JP2004501139A (ja) 2004-01-15
WO2001098277A3 (en) 2002-06-13
AR032353A1 (es) 2003-11-05
DE60108754D1 (de) 2005-03-10
AP2001002192A0 (en) 2002-12-21
MA26914A1 (fr) 2004-12-20
PE20020257A1 (es) 2002-04-08
ECSP024393A (es) 2003-02-06
NO20026166L (no) 2002-12-20
DE60108754T2 (de) 2005-06-23
HUP0301120A2 (hu) 2003-08-28
EP1292591B1 (en) 2005-02-02
EE200200710A (et) 2004-06-15
ZA200210231B (en) 2004-02-12
SV2002000504A (es) 2002-10-24

Similar Documents

Publication Publication Date Title
ATE288431T1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE458731T1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60024649D1 (de) Verbindungen für die behandlung von ischämie
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE304358T1 (de) (s,s)-reboxetin zur behandlung von migränekopfschmerzen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60105614D1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1292591

Country of ref document: EP

REN Ceased due to non-payment of the annual fee